Annual Report Reveals Going Concern, Zero Revenue, and Soaring Losses for Patent Monetization Firm

summarizeSummary

Quest Patent Research Corp's 2025 annual report reveals a going concern warning, zero revenue, an $8.5 million net loss, and a $27.2 million working capital deficit, signaling severe financial distress and operational challenges.

check_boxKey Events

• Going Concern Warning Issued

  The independent auditors included a substantial doubt going concern explanatory paragraph in their report for the year ended December 31, 2025, citing a history of losses, deficiency in stockholders' equity, and working capital deficit.

• Zero Revenue in 2025

  The company generated no revenue from patent licensing fees for the year ended December 31, 2025, a sharp decline from $2.8 million in 2024, indicating a complete failure in its patent monetization efforts for the period.

• Net Loss Triples to $8.5 Million

  Net loss for 2025 surged to $8.5 million, up from $2.5 million in 2024, driven by increased litigation and licensing expenses, and a significant increase in amortization of intangible assets.

• Critical Working Capital Deficit

  The company reported a negative working capital of approximately $27.2 million as of December 31, 2025, severely impairing its ability to fund operations and acquire new intellectual property.

auto_awesomeAnalysis

Quest Patent Research Corp's annual report highlights severe financial distress, including a going concern warning from its auditors. The company reported no revenue for 2025, a significant increase in net loss to $8.5 million, and a substantial working capital deficit of $27.2 million. Its business model, which relies entirely on successful patent litigation, is proving unsustainable, with all revenue in prior years being consumed by litigation and funding costs. The company's ability to continue operations is severely impaired, and its heavy dependence on third-party funding, coupled with material weaknesses in internal controls due to limited staff, presents critical risks to investors. The substantial potential for future dilution from authorized shares further exacerbates the negative outlook.